

Notification concerning the General Meeting of Shareholders of Sopharma AD

Sofia, Bulgaria, April 11, 2018 - **Sopharma AD** (3JR: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) (**The Company**) notifies that the filed on March 29, 2018 in the Commercial Register invitation for convening the Regular General Meeting of Shareholders of Sopharma AD on 11 May was not announced in accordance with the requirement of Art. 223, para 5 of the Commercial Law and the GMS cannot be conducted on this date.

The Board of Directors will propose another date for the GMS and will take the appropriate actions to convene it in the shortest possible time.

Please, on the grounds of Art. 100k, para 1 of the Public Offering of Securities Act, to make the above information public.

1×	11-
(1/)	RNOT
	UNS CON
D. L. C. Marshave	12 60 8
Pelagia Viatcheva	
Investor Relations I	Director, Hy Jak
	and the second of the

Sopharma AD

Information about the company

Sopharma AD

85 years tradition and modern approach – modern production, European quality standards, corporate social responsibility. Sopharma has an active and crucial role in raising standards of everyday life, in making people healthier, happier and safer. Sopharma AD continuously invests in technologies, innovation, research and science. We establish a constant and effective dialogue with all the actors in the pharmaceutical industry that contribute to the improvement of the health care system.

The company produces and markets medicinal substances and dosage forms; conducts research, engineering and implementation activities in the field of phytochemistry, chemistry and pharmaceuticals. Sopharma AD provides services related to production, as well as to ancillary and service activities.

The Company has a portfolio of more than 210 products: mainly generics and 15 original products, of which 12 products are phyto-based.

Sopharma Group

Sopharma Group is a vertically integrated healthcare business that operates in important sectors such as pharmaceuticals production, hospital supplies, pharmaceutical distribution (GDP standardized) and others. Sopharma and its production subsidiaries have 12 pharmaceutical plants in Bulgaria, complying with EU requirements – GMP and a factory in Ukraine certified by local authorities.

Sofia, Bulgaria 5 Lachezar Stanchev Str. Sopharma Business Towers, Tower A www.sopharmagroup.com tel: +359 (0) 2 4055 200; +359 (0) 8134 200 fax: +359 (0) 2 4055 141; +359 (0) 8134 141